Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity.

Abstract

HomeHypertensionVol. 76, No. 1Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBGnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity Tao Yang, Saroj Chakraborty, Piu Saha, Blair Mell, Xi Cheng, Ji-Youn Yeo, Xue Mei, Guannan Zhou, Juthika Mandal, Rachel Golonka, Beng San Yeoh, Vasanta Putluri, Danthasinghe Waduge Badrajee Piyarathna, Nagireddy Putluri, Cameron G. McCarthy, Camilla F. Wenceslau, Arun Sreekumar, Andrew T. Gewirtz, Matam Vijay-Kumar and Bina Joe Tao YangTao Yang From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Saroj ChakrabortySaroj Chakraborty From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Piu SahaPiu Saha From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Blair MellBlair Mell From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Xi ChengXi Cheng From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Ji-Youn YeoJi-Youn Yeo From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Xue MeiXue Mei From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Guannan ZhouGuannan Zhou From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Juthika MandalJuthika Mandal From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Rachel GolonkaRachel Golonka From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Beng San YeohBeng San Yeoh From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Vasanta PutluriVasanta Putluri Search for more papers by this author , Danthasinghe Waduge Badrajee PiyarathnaDanthasinghe Waduge Badrajee Piyarathna Arun Sreekumar (Department of Molecular Cell Biology, Dan L Duncan Comprehensive Cancer Center, and Center for Experimental Therapeutics and Metabolism, Baylor College of Medicine, Houston, TX) Vasanta Putluri (Advanced Technology Core, Baylor College of Medicine, Houston, TX) Nagireddy Putluri (Department of Molecular Cell Biology, Advanced Technology Core, and Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX) Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX (D.W.B.P.) Search for more papers by this author , Nagireddy PutluriNagireddy Putluri Search for more papers by this author , Cameron G. McCarthyCameron G. McCarthy From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Camilla F. WenceslauCamilla F. Wenceslau From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author , Arun SreekumarArun Sreekumar Search for more papers by this author , Andrew T. GewirtzAndrew T. Gewirtz Center for Inflammation, Immunity, and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA (A.T.G.). Search for more papers by this author , Matam Vijay-KumarMatam Vijay-Kumar From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author and Bina JoeBina Joe Correspondence to: Bina Joe, Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Block Health Science Bldg. Rm 237, 3000 Arlington Ave, Toledo, OH 43614. Email E-mail Address: [email protected] From the Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH (T.Y., S.C., P.S., B.M., X.C., J.-Y.Y., X.M., G.Z., J.M., R.G., B.S.Y., C.G.M., C.W., M.V.-K., B.J.) Search for more papers by this author Originally published19 May 2020https://doi.org/10.1161/HYPERTENSIONAHA.120.15360Hypertension. 2020;76:e1–e3Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: May 19, 2020: Ahead of Print The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel coronavirus named severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has led to an unprecedented medical crisis. Current lack of data from experimental animals makes it difficult to understand the pathophysiological mechanisms of COVID-19. A clinical study from COVID-19–positive patients in Hubei, China revealed that 46% presented with gastrointestinal problems.1 Also, SAR-CoV-2 viral RNA has been detected in the stools of patients with COVID-19. These data suggest the underestimated importance of intestinal infection in SARS-CoV-2-induced severe respiratory response.2ACE2 (angiotensin-converting enzyme 2), the receptor for SARS-CoV-2,3 is best known for its role in blood pressure regulation. Additionally, ACE2 has another important function of curbing intestinal inflammation. Ace2−/− mice with a reshaped gut microbiota were susceptible to intestinal inflammation.4 Transfer of the Ace2−/− gut microbiota to germ-free (GF) mice worsened colitis pathogenesis,4 suggesting gut microbiota-mediated protective effects of ACE2. These gastrointestinal benefits of ACE2 may be masked during coronavirus infection, where its expression in the intestine represents a possible avenue for viral entry. We speculated that gut microbiota, which is highly variable between individuals could be an additional factor modulating colonic Ace2 expression and thereby influencing COVID-19 infectivity.MethodsAnimalsSeven-week-old male GF Sprague Dawley (SD) rats (N=5) and GF rats co-housed with conventional SD rats for 10 days (conventionalized GF [GFC]; N=6) were obtained from Taconic Biosciences (https://www.taconic.com/). They were immediately sacrificed with excess of isoflurane anesthesia upon arrival at the University of Toledo. Fecal samples were collected from the colon for analysis.16S rRNA Gene SequencingFecal DNA was extracted from fecal pellet. PCR library preparation, 16S rRNA gene sequencing, and analysis were performed as previously described.5Real-Time PCRA total of 1000 ng of RNA from each sample was used to synthesize cDNA using high-capacity cDNA Reverse Transcription Kit (#15596026, Thermo Fisher Scientific, Waltham, MA). The primers used are: Ace2 forward ACCCTTCTTACATCAGCCCTACTG, reverse TGTCCAAAACCTACCCCACATAT, and Gapdh forward ACCACAGTCCATGCCATCAC, reverse TCCACCACCCTGTTGCTGTA.Serum Lcn2 MeasurementSerum Lipocalin 2 was measured by DuoSet ELISA kits from R&D Systems (#DY3508, Minneapolis, MN) according to the manufacturer’s protocol.Flow CytometrySingle-cell suspension was stained with APC Mouse Anti-Rat CD11b (#562102, BD Bioscience, Franklin Lakes, NJ) and PE Mouse Anti-Rat Granulocytes (#550002, BD Bioscience, Franklin Lakes, NJ) before flow cytometer analysis (Accuri c6; BD Biosciences, Franklin Lakes, NJ). Results were presented as the percentage of CD11b+ Granulocytes+ population from the cells gated in the forward versus side scatter plot.Correlation AnalysisThe Fragments Per Kilobase of transcript per Million mapped reads (FPKM) data from Wistar Kyoto and spontaneously hypertensive rats colonic epithelium were obtained from the previous study.6 The Spearman r correlation analysis was performed using Graphpad 8.3.0 (538) (Graphpad Software, San Diego, CA) on the combined data from both Wistar Kyoto and spontaneously hypertensive rats.Results and DiscussionTo test the hypothesis that microbiota influences Ace2 expression, we compared two groups of concomitantly raised gnotobiotic (germ-free,GF) rats with one group acquiring gut microbiota through co-housing for 10 days with conventional specific pathogen-free rats. 16S rRNA sequencing analysis of fecal samples confirmed successful colonization of 9 bacterial phyla in the GFC rats (Figure [A]). Reconstitution of the gut microbiota for 10 days markedly decreased the colonic Ace2 expression in GFC rats, compared with GF rats (Figure B). As the only variable between the 2 groups was the presence or absence of the microbiota, our observation indicates that the gut microbiota colonized in the GFC rats caused the decrease in colonic Ace2 expression. Whether this is directly or indirectly occurring via microbial metabolites remains unknown. The conventionalization also resulted in increasing systemic inflammatory tone in GFC compared with GF rats. This was demonstrated by significantly higher levels of lipocalin 2 (Lcn2) (Figure [C]) and neutrophilia determined by an elevated population of CD11b+Granulocyte+ cells (Figure [D]). In support of altered ACE2 expression impacting metabolism in the gut,4 a metabolomic analysis showed that compared with GF, GFC rats had higher levels of tryptophan metabolites, kynurenic acid, and hydroxy kynurenine (Figure [E]). Considering that individuals with preexisting conditions, including hypertension, are at higher risk for SARS-CoV-2 infection, we next examined whether colonic Ace2 expression was altered in a well-validated rat model of hypertension. A Spearman correlation analysis using the colonic gene expression profile from Wistar Kyoto rats and spontaneously hypertensive rats6 found that colonic Ace2 levels were inversely correlated with both Lcn2 and NOD-like receptor family CARD domain containing 5 (Nlrc5), which encodes a protein involved in antiviral responses (Figure [F]).Download figureDownload PowerPointFigure. A, Gut microbial composition at the phylum level in conventionalized GF (GFC) rats. Gut microbial compositions were analyzed by 16S rRNA gene sequencing and taxonomy assignments were based on Greengenes as reference. No phyla were detected in GF rats. B, Decreased Ace2 expression in GFC rats. The colonic expression of Ace2 was determined by real-time PCR and normalized to Gapdh. *P<0.05, unpaired t-test. C, Increased level of Lcn2 in serum from GFC rats. Hemolysis-free sera were obtained by centrifugation at 10 000 rpm, 10 min, 4°C. Lcn2 level in serum was determined by ELISA. *P<0.05; unpaired t-test. D, Increased proportion of CD11b+Granulocyte+ cells in peripheral blood of GFC rats. Whole blood was lysed with red blood cell lysis buffer and stained for CD11b+Granulocyte+ cells. ***P<0.001; unpaired t-test. E, Increased kynurenic acid and 3-hydroxy kynurenine in serum of GFC rats. Targeted metabolomic analyses were performed by HPLC-MS to measure the amount of kynurenic acid and 3-hydroxy kynurenine. The data were normalized with internal standards and log2-transformed per-sample basis. * and ** indicate P<0.05 and <0.01, respectively; unpaired t-test. F, Negative correlative expression of Ace2 with Lcn2 and Nlrc5 in the rats. The correlation analysis was performed on combined data from Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). The expression levels of Ace2, Lcn2 and Nlrc5 in the WKY and SHR were evaluated by RNA-seq and presented as FPKM.6In light of the current insufficient animal data on COVID-19, our results, although introductory, are timely and significant for 4 reasons. (1) This is the first demonstration of direct modulation of colonic ACE2 by the gut microbiota in the rat, which is closer in gut microbial composition and function to human than mouse.7 (2) This work lays the scientific foundation for examining the variability in gut microbial composition as a factor impacting susceptibility to COVID-19. (3) There is a close, strong relationship between hypertension and the gut microbiota.8,9 Therefore, administering broad-spectrum antibiotics to combat bacterial infection in COVID-19 may be given a second thought as this may increase Ace2 expression in patients. (4) Our data demonstrating an inverse correlation of colonic Ace2 with Lcn2 and Nlrc5, coupled with the previous finding that oral administration of ACE inhibitor significantly re-shaped gut microbiota,10 indicates that elevated colonic ACE2 in hypertensive patients on ACE inhibitor11 may also present with a weakened intestinal immune response depending on the extent of gut dysbiosis.In summary, this study clearly showed that gut microbiota represents a critical factor for the regulation of colonic Ace2 expression and associated colonic and systemic factors that likely contribute to the pathology of the gut-lung axis during COVID-19. Therefore, further studies are necessary to examine the gut microbial composition and its role in ACE2 expression in the COVID-19 susceptible and resistant populations, which would importantly inform on better clinical management of COVID-19.Sources of FundingThis work was supported by the National Institutes of Health R01HL143082 (B. Joe), R00GM118885 (C.F. Wenceslau), R01CA219144 (M. Vijay-Kumar), Biocodex Microbiota Foundation United States (T. Yang), DK083890 and DK099071 (A.T. Gewirtz), and the American Heart Association 18POST34060003 (C.G. McCarthy). The metabolomics core at Baylor College of Medicine was supported by the Cancer Prevention and Research Institute of Texas Core Facility Support Award RP170005 “Proteomic and Metabolomic Core Facility,” National Cancer Institute Support Grant P30CA125123, and intramural funds from the Dan L. Duncan Cancer Center.DisclosuresNone.FootnotesCorrespondence to: Bina Joe, Department of Physiology and Pharmacology, Microbiome Consortium, Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, Block Health Science Bldg. Rm 237, 3000 Arlington Ave, Toledo, OH 43614. Email bina.[email protected]edu